- Indivior Wednesday warned that the impact from the launch of a generic version of its opioid addiction treatment 'could be materially higher' in 2018 after first-half net profit slipped 6%.

The company said the adverse impact on 2018 net revenue of generic versions of Suboxone Film was anticipated to be at least $25m but 'could be materially higher'.

For the six months to 30 June, net profit fell 6% to $162m from $153m year earlier, net revenue fell by 5% to $524m from $553m.

The company blamed the fall in revenue on tactical rebating and unfavourable mix due to increased growth in its most price sensitive channel (Medicaid). This more than offset both strong US market growth, largely driven by the Medicaid channel, and rest of world growth.

The company was pinning its hopes on the another version of its opioid addiction treatment, Sublocade.

'Our primary focus is to ensure the successful progression of Sublocade as it begins its transformation of the treatment of opioid use disorder,' Shaun Thaxter, CEO of Indivior. At 8:10am: [LON:INDV] Indivior Plc share price was -44.3p at 289.2p

Story provided by